Targeted Therapeutics in Melanoma

  • Thomas F. Gajewski
  • F. Stephen Hodi

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Advances in Melanoma Biology

    1. Front Matter
      Pages 1-1
    2. Michael A. Davies
      Pages 3-15
    3. Mohammed Kashani-Sabet
      Pages 17-25
  3. Signaling Molecules as Molecular Targets

    1. Front Matter
      Pages 41-41
    2. Nageatte Ibrahim, F. Stephen Hodi
      Pages 43-61
    3. Paul B. Chapman, Keith Flaherty
      Pages 63-76
    4. John T. Lee, Meenhard Herlyn
      Pages 77-87
    5. Maciej Kujawski, Gregory Cherryholmes, Saul J. Priceman, Hua Yu
      Pages 89-105
    6. Peter Hersey, Xu Dong Zhang
      Pages 125-153
    7. Daniel S. Chen
      Pages 155-184
  4. Rational Immunotherapy Approaches in Melanoma

    1. Front Matter
      Pages 185-185
    2. Nicolas van Baren, Jean-François Baurain, Francis Brasseur, Pierre G. Coulie
      Pages 187-205
    3. Pedro Romero, Daniel E. Speiser
      Pages 207-232
    4. Jessica Ann Chacon, Patrick Hwu, Laszlo G. Radvanyi
      Pages 233-272
    5. Arvin S. Yang, Jedd D. Wolchok
      Pages 273-289
    6. Evan J. Lipson, Janis M. Taube, Lieping Chen, Suzanne L. Topalian
      Pages 291-306
    7. Andrew Weinberg, Robert H. Vonderheide, Mario Sznol
      Pages 307-331

About this book

Introduction

Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.

The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.

This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Keywords

B-Raf CTLA-4 Immunotherapy Melanoma Molecularly-guided Immunotherapies PD-1 Signal Transduction Inhibitors Skin Cancer Targeted Therapy c-kit mAbs

Editors and affiliations

  • Thomas F. Gajewski
    • 1
  • F. Stephen Hodi
    • 2
  1. 1., PathologyUniversity of ChicagoChicagoUSA
  2. 2., Melanoma Disease CenterDana-Farber Cancer InstituteBostonUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-61779-407-0
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-61779-406-3
  • Online ISBN 978-1-61779-407-0
  • About this book